This article provides the full transcript of Biodesix's earnings call for the second quarter of 2026.

Biodesix, Inc. conducted its Q1 2026 earnings call, summarizing its financial outcomes for the quarter. The report highlighted the company's performance in the biotechnology sector.

Biodesix has released highlights from its second-quarter earnings call, detailing its financial performance and advancements.

The key points from Biodesix's fourth-quarter earnings call have been published, outlining the company's financial and business developments.

Canaccord has raised its price target for Biodesix (BDSX), citing increased revenue assumptions for the company. This revision indicates an improved financial outlook for Biodesix.

Several companies, including Biodesix, Baldwin Insurance Group, CNA Financial, and Leidos, have announced their latest financial results or declared dividends. Other firms like Liquidia Corporation and Descartes have set dates for their upcoming earnings reports.

Biodesix announced its latest financial results, reporting a GAAP EPS of -$0.49, beating estimates by $0.38, and revenue of $28.7 million, surpassing forecasts by $2.45 million.